Nippon Shinyaku (4516) FY2027 Q1 Earnings Report

Quick View

Executive Summary

In FY2027 Q1, Nippon Shinyaku continued to deliver higher revenue and earnings, primarily driven by growth in the Pharmaceuticals Business. However, earnings growth was slightly slower than revenue growth due to increased R&D investment and a decline in the gross margin. Revenue was ¥490.7B (+24.1% YoY), Operating Income was ¥123.1B (+22.1%), Profit Before Tax was ¥129.6B (+23.4%), and Net Income was ¥101.1B (+22.4%). The primary driver of revenue growth was a 26.6% increase in revenue from the Pharmaceuticals Business. The factors behind earnings growth lagging revenue growth were a 48.6% increase in R&D expenses and a 410bp decline in the gross margin.

Factors Affecting Business Performance

【Revenue】Revenue increased 24.1% YoY to ¥490.7B. Revenue from the Pharmaceuticals Business grew to ¥432.6B (+26.6% YoY), driving growth as the core business and accounting for 88.2% of consolidated revenue. Revenue from the Functional Food Business increased 8.0% YoY to ¥58.1B, representing relatively moderate growth.

【Profit and Loss】Operating Income was ¥123.1B (+22.1% YoY), Profit Before Tax was ¥129.6B (+23.4%), and Net Income was ¥101.1B (+22.4%). Gross profit was ¥313.4B, corresponding to a gross margin of 63.9%, down 4.1pt from 68.0% in the same period of the previous year. R&D expenses increased significantly to ¥92.0B (+48.6% YoY; 18.7% of revenue). Together with the decline in the gross margin, this caused Operating Income growth to fall below the revenue growth rate. Meanwhile, the ¥13.6B increase in other income and the decline in other expenses supplemented Operating Income. Net Income was secured after corporate tax expense, with an effective tax rate of 22.0%. Although revenue and earnings increased, the fact that earnings growth fell below revenue growth indicates that higher costs and investment are placing some pressure on profitability.

Segment Analysis

The Pharmaceuticals Business generated revenue of ¥432.6B (+26.6% YoY) and Operating Income of ¥112.8B (+13.5%), maintaining high profitability with a 26.1% operating margin, while profit growth was somewhat slower than revenue growth. The Functional Food Business generated revenue of ¥58.1B (+8.0%) and Operating Income of ¥2.6B (+57.5%), delivering substantial earnings growth despite its low profitability, with a 4.5% operating margin. The Pharmaceuticals Business accounted for 97.7% of consolidated segment profit, indicating that the majority of business performance depends on developments in the Pharmaceuticals Business.

Key Financial Indicators

【Profitability】The Operating Income margin was 25.1%, down 0.4pt from 25.5% in the same period of the previous year, but remained at a high level. The Net Income margin was 20.6% (20.9% in the same period of the previous year), while the gross margin was 63.9% (68.0% in the same period of the previous year), down 4.1pt.【Cash Flow Quality】Operating Cash Flow (OCF) was only ¥18.3B, and the OCF-to-Net Income ratio was low at 0.18x, indicating that earnings for the quarter had not been sufficiently converted into cash. The primary factors were a ¥43.4B increase in trade receivables and ¥73.3B in corporate tax payments.【Investment Efficiency】Annualized ROE was 13.7%, while R&D expenses were ¥92.0B (18.7% of revenue), up from 15.6% in the same period of the previous year, indicating an acceleration of growth investment.【Financial Soundness】The Equity Ratio was 85.6%, and the company held ¥727.0B in cash and cash equivalents. Its debt-to-equity ratio was approximately 0.17x, representing an extremely conservative capital structure.

Cash Flow Analysis

OCF was ¥18.3B, a significant decrease from ¥68.0B in the same period of the previous year. Cash flow from operating activities before tax payments was ¥84.9B, but ¥73.3B in corporate tax payments was a major drain. In terms of working capital, a ¥43.4B increase in trade receivables and a ¥19.6B decrease in trade payables resulted in cash outflows, while a ¥4.5B decrease in inventories provided partial support. Investing Cash Flow was an outflow of ¥23.2B, mainly comprising ¥12.0B for the acquisition of property, plant and equipment and ¥16.0B for the acquisition of intangible assets. Financing Cash Flow was an outflow of ¥43.7B, of which dividend payments of ¥39.5B accounted for the majority. As a result, Free Cash Flow was negative ¥4.8B, indicating that internally generated funds during the quarter were insufficient to cover investment and dividend payments. Cash and cash equivalents remained substantial at ¥727.0B, providing significant short-term financial capacity.

Earnings Quality

Profit for the quarter was primarily driven by the increase in Operating Income, and no material one-off factors corresponding to extraordinary gains or losses have been explicitly identified. Other income increased significantly to ¥13.6B from ¥1.7B in the same period of the previous year, while other expenses declined to ¥1.2B from ¥7.9B. These non-core factors made a certain contribution to the increase in Operating Income. Financial income of ¥6.9B exceeded financial expenses of ¥0.4B, resulting in Profit Before Tax exceeding Operating Income by ¥6.5B. From an accruals perspective, OCF was only ¥18.3B against Net Income of ¥101.1B, resulting in a low OCF-to-Net Income ratio of 0.18x. This divergence was primarily attributable to the increase in trade receivables and the temporary increase in corporate tax payments, indicating that the timing lag in cash conversion requires attention when assessing earnings quality. Comprehensive Income was ¥80.2B, below Net Income of ¥101.1B, mainly due to a ¥22.1B valuation loss on financial assets measured at fair value through other comprehensive income.

Earnings Forecast and Guidance

The full-year earnings forecast is Revenue of ¥2000.0B, Operating Income of ¥380.0B (+7.1% YoY), and EPS of ¥449.55. Progress in Q1 was 24.5% for Revenue and 32.4% for Operating Income. Compared with the standard quarterly progress rate of 25%, Operating Income is tracking 7.4pt ahead of schedule. However, the earnings forecast has not been revised, and management has maintained its full-year plan. Q1 earnings growth of +22.1% is substantially above the full-year plan growth rate of +7.1%. The pace of increase in R&D expenses and trends in the gross margin, and how these factors will affect the second half, will be key areas for monitoring future progress.

Shareholder Returns

Dividend payments during Q1 amounted to ¥39.5B. The full-year dividend forecast is ¥124 per share, an increase from the previous fiscal year’s actual dividend (the annual dividend as of the same period of the previous year was ¥62, which can be compared on a half-year equivalent basis). The Payout Ratio against the full-year forecast EPS of ¥449.55 is approximately 27.6%, representing a level with sufficient headroom relative to earnings. Free Cash Flow during the quarter was negative ¥4.8B, meaning that dividends could not be covered solely by cash generated from operating activities. However, the company’s financial foundation, including ¥727.0B in cash and cash equivalents and an Equity Ratio of 85.6%, supports the sustainability of dividends. No revision was made to the dividend forecast during the quarter.

Risk Factors

1. Business concentration risk: The Pharmaceuticals Business accounts for 88.2% of consolidated revenue and 97.7% of segment profit. As a result, consolidated performance is highly sensitive to sales trends for key products and changes in the drug pricing system.

2. Delayed cash conversion: The OCF-to-Net Income ratio was low at 0.18x, while trade receivables increased by ¥43.4B and trade payables decreased by ¥19.6B. The fact that cash-generation capacity has not kept pace with the strength of the income statement requires monitoring.

3. Increased R&D investment and declining gross margin: R&D expenses reached ¥92.0B (+48.6% YoY; 18.7% of revenue), while the gross margin declined to 63.9% from 68.0% in the same period of the previous year, a decrease of 4.1pt. How these investments will translate into future earnings will be a key issue going forward.

Industry Benchmark (Reference; Compiled by the Company)

Profitability and Returns

The company’s profitability is significantly above the industry median, with both its Operating Income margin and Net Income margin ranking among the highest in the industry.

Growth and Capital Efficiency

The revenue growth rate also substantially exceeds the industry median, positioning the company among the industry’s high-growth group.

※Source: Compiled by the company

Key Takeaways from the Earnings

1. Revenue and earnings growth have continued, but the 48.6% increase in R&D investment and the 4.1pt decline in the gross margin have resulted in earnings growth falling below revenue growth. The balance between growth investment and profitability will be a key area of focus going forward.

2. The OCF-to-Net Income ratio was low at 0.18x, and profit for the quarter was not sufficiently converted into cash due to the increase in trade receivables and the impact of corporate tax payments. The sustainability of the divergence between earnings and cash flow should be closely monitored.

3. The company has a strong financial foundation, with an Equity Ratio of 85.6% and ¥727.0B in cash and cash equivalents, providing substantial capacity to absorb short-term cash flow fluctuations. Progress against the full-year plan is also favorable, while management has maintained the plan without revision.

Theoretical Share Price (Reference Value)

Sensitivity: ¥4,490–¥4,757 at ±1% for the cost of equity, and ¥4,615–¥4,629 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated values based solely on publicly disclosed data; these are not forecasts of market prices or recommendations for specific investment actions, and do not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---